The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Chronic Pain |
| Therapuetic Areas: | Musculoskeletal |
| Healthy: | No |
| Age Range: | 18 - 55 |
| Updated: | 3/27/2019 |
| Start Date: | May 1, 2019 |
| End Date: | December 31, 2019 |
| Contact: | Stephen Wagner, MD |
| Email: | swagner2@hmc.psu.edu |
| Phone: | 717-531-0003 |
This present investigation aims to determine whether a transversus abdominous plane(TAP)
block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section
decreases post-operative pain. The hypothesis is that performance of the TAP block with
liposomal bupivacaine will decrease post-operative narcotic use.
block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section
decreases post-operative pain. The hypothesis is that performance of the TAP block with
liposomal bupivacaine will decrease post-operative narcotic use.
Inclusion Criteria:
- Patients >18 years of age
- Scheduled cesarean section with or without bilateral tubal ligation
- Planned performance of a Pfannenstiel incision
- Patients are schedule to have a cesarean section with a member of the Women's Health
or Maternal and Fetal Medicine Departments at Penn State University Hershey S. Medical
Center
Exclusion Criteria:
- History of opioid use
- History of chronic pain syndrome
- Use of general anesthesia during cesarean delivery
- Postoperative SICU admission
- Postpartum hemorrhage (defined as an Estimated Blood Loss of greater then 1,000mL upon
completion of the cesarean section)
We found this trial at
1
site
Click here to add this to my saved trials
